We strive to foster an environment where diverse perspectives and backgrounds are recognized, appreciated and embraced. Click through to hear from some of our colleagues. Our 2023 Diversity, Equity and Inclusion Annual Report is now available at the link here: https://bit.ly/3yiZasy
Foundation Medicine
Biotechnology Research
Boston, Massachusetts 79,372 followers
Find Answers. Take Action. #WeAreFMI
About us
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit us at www.FoundationMedicine.com or follow @FoundationATCG on Twitter. Community Guidelines: bit.ly/FMICommunityGuidelines
- Website
-
http://www.foundationmedicine.com
External link for Foundation Medicine
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Boston, Massachusetts
- Type
- Privately Held
- Founded
- 2010
- Specialties
- molecular information, cancer genomics, next-generation sequencing, precision medicine, comprehensive genomic profiling, and oncology
Locations
-
Primary
400 Summer St
Boston, Massachusetts 02210, US
-
7010 Kit Creek Road
Morrisville, NC 27560, US
Employees at Foundation Medicine
-
Michael Travers
Hello
-
Kathleen Gammon
AI savvy Release Manager & Scrum Master at Foundation Medicine
-
Allan Mohess
VP, Commercial Operations | Commercial Excellence and Sales Operations in Biotech, Healthcare & Software | Drives Growth through Strategic Business…
-
John Breen
Associate Director, R&D Automation Engineering and LIMS at Foundation Medicine
Updates
-
Today we recognize World Lung Cancer Day. In our work to transform cancer care, we are committed to spreading awareness and knowledge around lung cancer. We’re proud to support the lung cancer community and organizations such as GO2 for Lung Cancer in all of their efforts in research, education and advocacy. Hear more perspectives and learn about the progress that has been made in lung cancer diagnosis, treatment and outcomes at the link here: https://bit.ly/3A4O0YV
-
New Publication – Proud to share that recent #research published in The Lancet showcased positive results of CUPISCO, a randomized, precision oncology study designed to prospectively assess the efficacy of molecularly guided therapy in patients w/ unfavorable subsets of cancer-of-unknown-primary. Click the link here to read the full publication and to learn more: https://bit.ly/3yoGFml
-
-
Our passion to advance cancer care stems from the individuals that make up our team. We’re proud to highlight two of our dedicated account executives, Megan and Ethan, who are celebrating significant milestones — Megan’s 20 years cancer-free and Ethan’s 10 years cancer-free. Join us in honoring these remarkable individuals whose resilience and dedication inspire us all: https://bit.ly/3yu4rNL #WeAreFMI
-
-
Wishing our 2024 summer interns a very happy National Internal Day! Thank you all so much for the hard work and dedication you bring to Foundation Medicine. #WeAreFMI
-
In an ever-changing environment, we are committed in our efforts to ensuring Foundation Medicine is a diverse and inclusive place for all. Our third annual Diversity, Equity and Inclusion (DE&I) report reflects upon the progress we have made in the last year, our reflections on this progress, and our continued efforts to do more within our community and beyond: https://bit.ly/4cHCkJP #WeAreFMI
-
Results from a new study showcase the value of circulating tumor DNA (ctDNA) monitoring as an additional approach to evaluating clinical response to certain treatments for patients with metastatic castration resistant #prostatecancer. Data indicates that ctDNA tumor fraction can complement prostate-specific antigen (PSA) testing and conventional radiographic assessments while also serving as a strong prognostic factor across treatment time points. Read more in our latest #research spotlight: https://bit.ly/4cXlczG
-
We’re honored to celebrate the LGBTQIA+ community in June and beyond. Last month, colleagues, their families and friends, came together to commemorate #Pride month through various activities and events. Read through the highlights here: https://bit.ly/45X4pKI
-
-
Approval Announcement – proud to share that our blood-based, liquid biopsy test has been approved by the FDA as a companion diagnostic to help identify patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer who may be appropriate for a specific targeted therapy. This decision follows the approval of our tissue-based test for the same therapy in August 2023. Learn more: https://bit.ly/45OTClB